Roy Gerth van Wijk,Ludger Klimek,Oliver Pfaar
Roy Gerth van Wijk
110 years after the classical study by Noon, numerous studies have confirmed the efficacy of allergen immunotherapy. A variety of clinical endpoints have been used in these trials. This review gives an overview of clinical endpoints for ran...
Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps [0.03%]
真实世界变应原免疫治疗的证据：利用移动医疗应用程序进一步开展研究
Bernardo Sousa-Pinto,Oliver Pfaar,Jean Bousquet
Bernardo Sousa-Pinto
Aim: The efficacy and safety of allergen immunotherapy (AIT) in allergic rhinitis has been classically assessed using randomized controlled trials (RCTs). However, RCTs may have limitations in their external validity, and...
Tobias Ankermann,Randolf Brehler
Tobias Ankermann
. Allergen immunotherapy (AIT) as a validated, disease-modifying treatment is nowadays a widely recommended therapy option for allergic rhinitis and allergic asthma. The registration of allergen extracts used for AIT is based on allergen st...
Benjamin Klein,Jan Christoph Simon,Regina Treudler
Benjamin Klein
Background: The therapy of severe food allergy so far consists mainly of allergen abstinence and emergency treatment. The use of anti-IgE antibodies represents a promising therapy. ...
Case Reports
Allergologie select. 2023 Feb 3:7:20-24. DOI:10.5414/ALX02372E 2023
Prospective, monocentric, observational study of the long-term effectiveness of omalizumab in chronic urticaria [0.03%]
在慢性荨麻疹中长期观察奥马利珠单抗疗效的单中心前瞻性观察研究
Stephan Traidl,Bettina Wedi
Stephan Traidl
Omalizumab, a monoclonal antibody targeting IgE, has been approved in 2014 for the treatment of H1 antihistamine-refractory chronic urticaria. Data on long-term effectiveness and predictive factors for treatment response are currently limit...
Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab [0.03%]
病例报告：用奥马利珠单抗和杜普利鲁玛成功治疗严重慢性自发性荨麻疹
Viktoria Puxkandl,Wolfram Hoetzenecker,Sabine Altrichter
Viktoria Puxkandl
Urticaria is a disease triggered by mast cells and characterized by recurrent symptoms such as wheals and/or angioedema. Most patients benefit from treatment with antihistamines (AH) or, if not effective enough, from additional therapy with...
Case Reports
Allergologie select. 2023 Jan 3:7:17-19. DOI:10.5414/ALX02382E 2023
Chronic recurrent wheals - If not chronic spontaneous urticaria, what else? [0.03%]
慢性反复发疹 - 如果不是慢性自发性荨麻疹，还会是什么呢？
Hanna Bonnekoh,Karoline Krause,Pavel Kolkhir
Hanna Bonnekoh
Chronic urticarial rash, mostly due to chronic spontaneous urticaria (CSU), is seen in up to 1 - 4% of the general population. Urticarial vasculitis (UV) and autoinflammatory syndromes, i.e., cryopyrin-associated periodic syndromes (CAPS) a...
Alpha-gal syndrome and delayed anaphylaxis after ingestion of red meat: A case report [0.03%]
红肉摄入后迟发型过敏性休克伴阿尔法半乳糖综合征：一例报道
Lea Caron,Valeria G R Ortolani,Eleonora Bono et al.
Lea Caron et al.
α-gal syndrome (AGS) is caused by the intake of products containing α-gal (galactose-α-1,3-galactose) like mammalian meat. Over the last decade, scientific literature about AGS has been increasing, but the true burden of cases is still u...
Case Reports
Allergologie select. 2022 Dec 15:6:299-303. DOI:10.5414/ALX02394E 2022
Stephanie Dramburg,Paolo Maria Matricardi,Oliver Pfaar et al.
Stephanie Dramburg et al.
In the recent past, digital healthcare technologies are experiencing a significant leap in development, with an additional unforeseen acceleration in implementation due to the SARS-CoV-2 pandemic. The increased use of mobile applications as...
Adherence in allergen immunotherapy: Current situation and future implications [0.03%]
过敏原免疫治疗中的依从性：现状与未来意义
Francesca Gehrt,Qingqing Xu,Ilaria Baiardini et al.
Francesca Gehrt et al.
Allergen immunotherapy (AIT) is the only disease-modifying treatment in allergy. However clinical trials as well as real-life studies revealed poor treatment adherence. This article is intended to provide an overview of the current literatu...